Newsroom

[WSJ] If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Now that the FDA has approved the Harvoni treatment from Gilead Sciencesand a $94,500 price for a 12-week regimen has been established, attention is turning toward AbbVie and the steps the big drug maker must take to win market share.

Read more

[PoliticoPro] Tennessee Medicaid Sees $100 Million in Sovaldi Costs

Tennessee Medicaid Director Darin Gordon said today that his state has a $700 million annual pharmacy budget and it has spent $100 million alone on hepatitis […]

Read more

[The Morning Consult] The Gilead Effect

Perhaps no company has done as much as Gilead to propel the issue of high drug prices onto center stage or to lay bare the pharmaceutical industry’s approach to pricing new drugs.

Read more

[WSJ] Will ‘Son of Sovaldi’ Cause State Medicaid Programs to Erect High Hurdles?

How might state Medicaid programs cope with a new and equally expensive hepatitis C treatment from Gilead Sciences.

Read more